株式会社ジーエヌアイグループ 2023年12月期 第３四半期 決算説明資料

This document is the financial results presentation for the third quarter of the fiscal year ending December 2023 for GNI Group, Inc. The company reported a record revenue of 20,547 million yen, a 61.0% increase compared to the same period last year, and an operating profit of 6,802 million yen, reflecting a 355.3% increase. Research and development expenses decreased by 2.3% year-on-year, indicating efficient management. GNI Group focuses on global pharmaceutical research and development, particularly in new drug development, aiming to provide hope to patients through innovative treatments.